Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Overview of attention for article published in Drug Safety, December 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog

twitter: 1 X user
patent: 2 patents

Citations

dimensions_citation: 41 Dimensions

Readers on

mendeley: 98 Mendeley

Summary News Blogs X Patents Dimensions citations

So far, Altmetric has seen 1 X post from an account with 1,025 followers.

Benefit–Risk Assessment of #Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia #openaccess #drugsafety #pharmacovigilance #ALL #Blincyto @AmgenOncology https://t.co/efxTSB91U8 https://t.co/zzoRUyQuez

Reply Repost Favourite